The percentage of penetration ranges from 0.69% to 1.3%, which may provide a good opportunity for tumor cell growth in the CNS.7 Thirdly, as the treatment duration increases, the likelihood of the development of several secondary resistance mechanisms to EGFR‐TKIs also increases.8, 9, 10 Based on these considerations, the treatment options for EGFR+ NSCLC patients with LM generally include an intial high‐dose of first or second‐generation EGFR‐TKIs, or a switch to a different EGFR‐TKI. The gene discussed is EGFR; the disease is neoplasm.